Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer

被引:0
|
作者
Zimmer, Philipp [1 ]
Esser, Tobias [1 ]
Lueftner, Diana [3 ,4 ]
Schuetz, Florian [5 ]
Baumann, Freerk T. [6 ]
Rody, Achim [7 ]
Schneeweiss, Andreas [8 ,9 ]
Hartkopf, Andreas D. [10 ]
Decker, Thomas [11 ]
Uleer, Christoph [12 ]
Stoetzer, Oliver J. [13 ]
Foerster, Frank [14 ]
Schmidt, Marcus [15 ]
Mundhenke, Christoph [16 ]
Steindorf, Karen [17 ]
Tesch, Hans [18 ]
Jackisch, Christian [19 ]
Fischer, Thomas [20 ]
Hanson, Sven [21 ]
Kreuzeder, Julia [21 ]
Guderian, Gernot [21 ]
Fasching, Peter A. [22 ]
Bloch, Wilhelm [2 ]
机构
[1] TU Dortmund Univ, Inst Sport & Sport Sci, Div Performance & Hlth Sports Med, Dortmund, Germany
[2] German Sport Univ Cologne, Dept Mol & Cellular Sports Med, Cologne, Germany
[3] Immanuel Hosp Mark Schweiz, Buckowrudersdorf, Germany
[4] Med Univ Brandenburg Theodor Fontane, Buckowrudersdorf, Germany
[5] Univ Hosp Heidelberg, Dept Obstet & Gynecol, Heidelberg, Germany
[6] Univ Hosp Cologne, Ctr Integrated Oncol, Dept Internal Med 1, Cologne, Germany
[7] Univ Hosp Schleswig Holstein, Dept Obstet & Gynecol, Lubeck, Germany
[8] Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[9] German Canc Res Ctr, Heidelberg, Germany
[10] Univ Hosp Tuebingen, Dept Womens Hlth, Tubingen, Germany
[11] Med Ctr Hematol & Oncol Ravensburg, Ravensburg, Germany
[12] Gynecol Grp Practice, Hildesheim, Germany
[13] Med Ctr Hematol & Oncol Munich, Munich, Germany
[14] Poliklin GmbH Chemnitz, Chemnitz, Germany
[15] Univ Med Ctr Mainz, Dept Obstet & Gynecol, Dept Conservat & Mol Gynecol Oncol, Mainz, Germany
[16] Bayreuth Hosp, Dept Obstet & Gynecol, Bayreuth, Germany
[17] German Canc Res Ctr, Div Phys Act Prevent & Canc, Heidelberg, Germany
[18] Ctr Hematol & Oncol Bethanien, Frankfurt, Germany
[19] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[20] Winicker Norimed GmbH Med Res, Nurnberg, Germany
[21] Novartis Pharm GmbH, Nurnberg, Germany
[22] Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
来源
BMC MEDICINE | 2024年 / 22卷 / 01期
关键词
Physical activity; Exercise; Breast cancer; Adverse events; Survival; Fatigue; Quality of life; QUALITY-OF-LIFE; EXERCISE; MORTALITY; ASSOCIATION; FATIGUE; METAANALYSIS; RECURRENCE; VALIDITY;
D O I
10.1186/s12916-024-03671-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general. Methods In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination. Results Compared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels. Conclusions Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue. Trial registration EUPAS9462. Registered 30th October 2012 "retrospectively registered."
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Ahmet Bilici
    Bala Basak Oven Ustaalioglu
    Serif Ercan
    Asuman Orcun
    Mesut Seker
    Taflan Salepci
    Mahmut Gumus
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 309 - 316
  • [32] Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes
    Lauren E. McCullough
    Jia Chen
    Yoon Hee Cho
    Nikhil K. Khankari
    Patrick T. Bradshaw
    Alexandra J. White
    Susan L. Teitelbaum
    Mary Beth Terry
    Alfred I. Neugut
    Hanina Hibshoosh
    Regina M. Santella
    Marilie D. Gammon
    Breast Cancer Research, 19
  • [33] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Tremblay, Gabriel
    BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
  • [34] Prediction of Progression-Free Survival and Response to Paclitaxel Plus Carboplatin in Patients With Recurrent or Advanced Cervical Cancer
    Hisamatsu, Takeshi
    Mabuchi, Seiji
    Yoshino, Kiyoshi
    Fujita, Masami
    Enomoto, Takayuki
    Hamasaki, Toshimitsu
    Kimura, Tadashi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (04) : 623 - 629
  • [35] Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
    Samaille, T.
    Bachelard, C. Moreau
    Coquan, E.
    du Rusquec, P.
    Paoletti, X.
    Le Tourneau, C.
    ESMO OPEN, 2022, 7 (01)
  • [36] Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    Chmielewska, Izabela
    Dudzinska, Marta
    Szczyrek, Michal
    Swirska, Joanna
    Wojas-Krawczyk, Kamila
    Zwolak, Agnieszka
    PLOS ONE, 2021, 16 (09):
  • [37] Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer
    Hempling, RE
    Piver, MS
    Eltabbakh, GH
    Recio, FO
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (05): : 447 - 451
  • [38] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Hirai, Takehiro
    Nemoto, Asuka
    Ito, Yoshinori
    Matsuura, Masaaki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 189 - 198
  • [39] Circulating Tumor Cells in Metastatic Breast Cancer: Monitoring Response to Chemotherapy and Predicting Progression-Free Survival
    Cheng, Jian-ping
    Yan, Ying
    Wang, Xiang-yi
    Lu, Yuan-li
    Yuan, Yan-hua
    Wang, Xiao-li
    Jia, Jun
    Ren, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (03) : 201 - 210
  • [40] Circulating Tumor Cells in Metastatic Breast Cancer:Monitoring Response to Chemotherapy and Predicting Progression-Free Survival
    Jian-ping Cheng
    Department of Medical Oncology
    ChineseJournalofCancerResearch, 2010, 22 (03) : 201 - 210